In a preclinical study of 6 germline TP53 mutated breast cancer patients who received adjuvant radiotherapy, 3 later developed ipsilateral breast recurrences, 4 developed contralateral breast cancers, 2 developed radiotherapy-induced cancers, and 2 developed new primaries (1 of which was an ipsilateral chest wall angiosarcoma and the other was a grade 2 ethmoidal leiomyosarcoma) [36]. The gene discussed is TP53; the disease is leiomyosarcoma.